Oncology

Get to Market Faster and
Modernize Oncology Treatment

You’re under pressure to get your molecule to market as fast as possible, with as little risk and cost as possible, so you can maximize market share and revenue. But there are significant shifts that are changing the way in which new drugs are developed.

The IV-to-SC trend is increasing

40 % of injectable drugs were approved with devices in 2018, compared to only 25% in 2011.¹

The patient experience Is increasingly critical.

The FDA’s patient-focused drug development (PFDD) help ensure patients’ preferences are incorporated throughout drug development. ²

The competition is Intensifying

There are more molecules than ever in the biologics pipeline, as well as more biosimilars now coming to market.³

The Challenges of Trying to Reduce Risk In Development

To expedite the development plan, many companies choose to stick with an IV therapy they’ve used before, because it’s tried and tested. But this doesn’t align with patient preferences. Meanwhile, your competition is marketing SC injection with syringes. While SC injection with syringes is closer to the mark when it comes to patient preference, it ultimately falls short, in part because it may still require a healthcare provider to administer the medication to the patient in a clinical setting.

What is the risk of this approach?

Alternative therapies that solve a similar clinical problem but with a better delivery system can quickly gain an advantage, Which can increase your risk of market success.

To elevate your focus to patient outcomes,

You need to modernize your delivery by using technology to enable fit-for-purpose, on-body devices and simplify the development process so you can protect your market position.

Talk to Our Team

To do that, you need to overcome two main challenges :

Which of the following are you feeling most acutely today?

Current delivery methods create a suboptimal patient experience and expensive total cost

The SC device development pathway Is complex

1. Based on FDA data from the Centre for Drug/Biologic Evaluation and Research.
2. PharmaCircle.
3. IMS Smart. US, UK, France, Germany, Italy and Spain. As of 30 June 2019; no IMS data for 2019.
4. Patients' Preferences for Subcutaneous Trastuzumab versus Conventional Intravenous Infusion for the Adjuvant Treatment of HER2- Positive Early Breast Cancer: Final Analysis of 488 Patients in the International, Randomized, Two-Cohort Prefer Study, Annals of Oncology, 2014.

West and the Diamond logo is a registered trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. © Copyright 2020 West Pharmaceutical Services, Inc.